S. Faivre

G. Calais, E. Baudin, E. Babin, 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[Preclinical studies of oxaliplatin in combination chemotherapy].

E. Raymond, S. Faivre, C. Louvet, 2001, Bulletin du cancer.

Sunitinib paves the way for targeted therapies in neuroendocrine tumors

E. Raymond, S. Faivre, P. Ruszniewski, 2009, Targeted Oncology.

Predictive Factors of Sensitivity to Elisidepsin, a Novel Kahalalide F-Derived Marine Compound

I. Bièche, E. Raymond, C. Galmarini, 2013, Marine drugs.

Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells

E. Raymond, S. Faivre, M. Serova, 2008, British Journal of Cancer.

Antiproliferative effects of sapacitabine (CYC682), a novel 2′-deoxycytidine-derivative, in human cancer cells

E. Raymond, C. Galmarini, S. Faivre, 2007, British Journal of Cancer.

Targeting the Tumor Microenvironment through mTOR Inhibition and Chemotherapy as Induction Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma: The CAPRA Study

E. Raymond, S. Faivre, C. Dreyer, 2022, Cancers.

A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.

Joon-Oh Park, A. Varghese, D. Melisi, 2019, Journal of Clinical Oncology.

Safety and evidence of activity of MSC1936369, an oral MEK1/2 inhibitor, in patients with advanced malignancies.

E. Raymond, A. Italiano, S. Faivre, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

First-in-human phase I safety, pharmacokinetic (PK), and pharmacodynamic (PD) analysis of the oral MEK-inhibitor AS703026 (two regimens [R]) in patients (pts) with advanced solid tumors.

E. Raymond, A. Italiano, S. Faivre, 2010 .

Sunitinib in hepatocellular carcinoma: redefining appropriate dosing, schedule, and activity end points.

E. Raymond, S. Faivre, C. Dreyer, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase 2 study of galunisertib, a novel transforming growth factor-beta (TGF-β) receptor I kinase inhibitor, in patients with advanced hepatocellular carcinoma (HCC) and low serum alpha fetoprotein (AFP).

G. Giannelli, E. Raymond, A. Santoro, 2016 .

Tyrosine kinase inhibition and grey hair

E. Raymond, C. Robert, J. Armand, 2003, The Lancet.

Pancreatic NETs: where do we stand now?

R. Salazar, S. Faivre, D. Castellano, 2014, Cancer and Metastasis Reviews.

[Advanced hepatocellular carcinoma: importance of clinical trials].

E. Raymond, S. Faivre, V. Aedo, 2015, Revue medicale suisse.

Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST)

E. Raymond, S. Faivre, C. le Tourneau, 2007, Therapeutics and clinical risk management.

Role of the endothelins and endothelin receptors in cancer cell signaling and angiogenesis

E. Raymond, S. Faivre, M. Serova, 2007, Targeted Oncology.

Epidermal Growth Factor Receptor Tyrosine Kinase as a Target for Anticancer Therapy

E. Raymond, J. Armand, S. Faivre, 2012, Drugs.

Benzofuran derivatives as anticancer inhibitors of mTOR signaling.

E. Raymond, S. Faivre, M. Serova, 2014, European journal of medicinal chemistry.

Cancer wars: natural products strike back

Qian Zhao, E. Raymond, S. Faivre, 2014, Front. Chem..

Reports of Clinical Benefit of Plitidepsin (Aplidine), a New Marine-Derived Anticancer Agent, in Patients With Advanced Medullary Thyroid Carcinoma

E. Raymond, S. Faivre, J. López-Martín, 2009, American journal of clinical oncology.

Unraveling galectin-1 as a novel therapeutic target for cancer.

E. Raymond, S. Faivre, S. Albert, 2014, Cancer treatment reviews.

Translational Rational for the Clinical Development of OTX-008: A Novel Drug That Inhibits Galectin-1 Expression in Human Cancer Models

E. Raymond, S. Faivre, M. Serova, 2012 .

PHASE III STUDY OF SUNITINIB VS PLACEBO IN PATIENTS (PTS) WITH ADVANCED, UNRESECTABLE PANCREATIC NEUROENDOCRINE TUMOR (NET)

Y. Bang, E. Raymond, Xin Huang, 2012 .

Evaluation of progression-free survival by blinded independent central review in patients with progressive, well-differentiated pancreatic neuroendocrine tumors treated with sunitinib or placebo.

E. Van Cutsem, E. Raymond, S. Faivre, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

846P PHASE III TRIAL OF SUNITINIB (SU) VERSUS PLACEBO (PBO) FOR TREATMENT OF PANCREATIC NEUROENDOCRINE TUMORS (NET): IMPACT OF SOMATOSTATIN ANALOGUE (SSA) TREATMENT ON PROGRESSION-FREE SURVIVAL (PFS)

E. Raymond, S. Faivre, D. Castellano, 2010 .

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer.

E. Raymond, C. Robert, J. Armand, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib

I. Bièche, E. Raymond, S. Faivre, 2016, Oncotarget.

Bioactive Flavaglines: Synthesis and Pharmacology

E. Raymond, C. Robert, S. Faivre, 2015 .

[Basaloid squamous cell carcinomas of the head and neck].

J. Klijanienko, P. Maingon, J. Thariat, 2009, Bulletin du cancer.

Phase I and Pharmacokinetic Study of Irofulven Administered Weekly or Biweekly in Advanced Solid Tumor Patients

E. Raymond, F. Goldwasser, S. Faivre, 2004, Clinical Cancer Research.

mTOR-targeted therapy of cancer with rapamycin derivatives.

E. Raymond, S. Faivre, E Raymond, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma

E. Raymond, S. Faivre, M. Serova, 2014, British Journal of Cancer.

Prognostic value of the chemokine receptor CXCR4 and epithelial-to-mesenchymal transition in patients with squamous cell carcinoma of the mobile tongue.

E. Raymond, S. Faivre, S. Albert, 2012, Oral oncology.

Oncologic outcomes, prognostic factor analysis and therapeutic algorithm evaluation of head and neck mucosal melanomas in France.

G. Calais, E. Baudin, E. Babin, 2019, European journal of cancer.

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer.

E. Raymond, J. Armand, S. Faivre, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preclinical and clinical development of novel agents that target the protein kinase C family.

E. Raymond, S. Faivre, M. Serova, 2006, Seminars in oncology.

[Targeted therapies in hepatocellular carcinoma].

E. Raymond, S. Faivre, C. Dreyer, 2010, Presse medicale.

Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer.

M. Ducreux, E. Raymond, J. Armand, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Imatinib mesylate can induce objective response in progressing, highly expressing KIT adenoid cystic carcinoma of the salivary glands.

E. Raymond, P. Berthaud, S. Faivre, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients.

J. Bonneterre, P. Viens, S. Faivre, 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Benzofuran derivatives as a novel class of inhibitors of mTOR signaling.

E. Raymond, S. Faivre, M. Serova, 2014, European journal of medicinal chemistry.

Molecular therapies for HCC: Looking outside the box.

R. Finn, L. Rimassa, S. Faivre, 2020, Journal of hepatology.

Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial.

Sung-Bae Kim, A. Dechaphunkul, É. Remenár, 2017, The Lancet. Oncology.

Understanding c-MET signalling in squamous cell carcinoma of the head & neck.

E. Raymond, S. Faivre, S. Albert, 2017, Critical reviews in oncology/hematology.

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

S. Faivre, L. Licitra, E. Winquist, 2013, The Lancet. Oncology.

A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors

E. Raymond, F. Goldwasser, S. Faivre, 2007, Investigational New Drugs.

Macrophages in the microenvironment of head and neck cancer: potential targets for cancer therapy.

V. Paradis, E. Raymond, S. Faivre, 2019, Oral oncology.

Molecular basis for sunitinib efficacy and future clinical development

G. Demetri, E. Raymond, S. Faivre, 2007, Nature Reviews Drug Discovery.

Markers involved in resistance to cytotoxics and targeted therapeutics in pancreatic cancer.

E. Raymond, S. Faivre, G. Batty, 2009, Cancer treatment reviews.

Cellular and molecular pharmacology of oxaliplatin.

E. Raymond, S. Chaney, S. Faivre, 2002, Molecular cancer therapeutics.

PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma

V. Paradis, E. Raymond, S. Faivre, 2020, Oncoimmunology.

Phase I and pharmacokinetic study of etaracizumab (Abegrin™), a humanized monoclonal antibody against αvβ3 integrin receptor, in patients with advanced solid tumors

E. Raymond, S. Faivre, M. Marty, 2008, Investigational New Drugs.

Focus on the role of the CXCL12/CXCR4 chemokine axis in head and neck squamous cell carcinoma

E. Raymond, S. Faivre, S. Albert, 2013, Head & neck.

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study.

E. Raymond, J. Douillard, Jun Suk Kim, 2009, The Lancet Oncology.

Perspectives of TGF-β inhibition in pancreatic and hepatocellular carcinomas

E. Raymond, S. Faivre, A. de Gramont, 2013, Oncotarget.

Predictive Biomarkers of Response to mTOR Inhibitors

E. Raymond, S. Faivre, C. Neuzillet, 2016 .

Protein kinase C α and δ are members of a large kinase family of high potential for novel anticancer targeted therapy

E. Raymond, S. Faivre, M. Serova, 2006, Targeted Oncology.

Stromal expression of SPARC in pancreatic adenocarcinoma

E. Raymond, S. Faivre, P. Hammel, 2013, Cancer and Metastasis Reviews.

Molecular targeted therapy of head and neck cancer: review and clinical development challenges.

L. Siu, S. Faivre, Lillian L Siu, 2007, European journal of cancer.

Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors

E. Raymond, J. Schellens, A. Italiano, 2020, Targeted Oncology.

Sunitinib in advanced pancreatic neuroendocrine tumors: latest evidence and clinical potential

Chantal Dreyer, E. Raymond, S. Faivre, 2012, Therapeutic advances in medical oncology.

Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.

Mohamed Bouattour, Laurent Castera, Chantal Dreyer, 2014, The oncologist.

Letter to the editor referring to the publication entitled "The role of antagonists of the PD-1:PD-L1/PD-L2 axis in head and neck cancer treatment" by Pai et al.

S. Faivre, P. Szturz, 2016, Oral oncology.

Phase I dose escalation and pharmacokinetic evaluation of two different schedules of LY2334737, an oral gemcitabine prodrug, in patients with advanced solid tumors

E. Raymond, H. Riess, S. Faivre, 2015, Investigational New Drugs.

New developments in multitargeted therapy for patients with solid tumours.

E. Raymond, S. Faivre, C. Tourneau, 2008, Cancer treatment reviews.

RhoA‐ and RhoD‐dependent regulatory switch of Gα subunit signaling by PAR‐1 receptors in cellular invasion

M. Mareel, E. Bruyneel, S. Faivre, 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

Optimal management of nasopharyngeal carcinoma

J. Armand, F. Janot, S. Faivre, 2004, Current opinion in oncology.

c-MET-mediated resistance to EGFR inhibitors in head and neck cancer: How to move from bench to bedside.

E. Raymond, S. Faivre, P. Szturz, 2016, Oral oncology.

Discovery of Sunitinib as a Multitarget Treatment of Cancer

E. Raymond, S. Faivre, C. Dreyer, 2012 .

Specificities and challenges of imaging response in pancreatic neuroendocrine tumors treated with targeted therapies

M. Ronot, V. Vilgrain, E. Raymond, 2012 .

Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development

E. Raymond, S. Faivre, C. Dreyer, 2010, Expert opinion on drug metabolism & toxicology.

Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01.

J. Machiels, N. Michoux, S. Faivre, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Benefit-Risk Assessment of Sunitinib in Gastrointestinal Stromal Tumours and Renal Cancer

E. Raymond, S. Faivre, C. Dreyer, 2009, Drug safety.

Effects of prolonged versus short-term exposure paclitaxel (Taxol) on human tumor colony-forming units.

E. Raymond, D. V. Von Hoff, G. Clark, 1997, Anti-cancer drugs.

Oxaliplatin: mechanism of action and antineoplastic activity.

E. Raymond, S. Chaney, S. Faivre, 1998, Seminars in oncology.

A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma

P. Galle, G. Giannelli, R. Kelley, 2019, Clinical and translational gastroenterology.

Targeting cancer cell metabolism in pancreatic adenocarcinoma

E. Raymond, S. Faivre, A. de Gramont, 2015, Oncotarget.

Insights on the CXCL12-CXCR4 axis in hepatocellular carcinoma carcinogenesis.

V. Paradis, E. Raymond, S. Faivre, 2014, American journal of translational research.

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors.

Suzanne F. Jones, Ian Judson, D. Rea, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

New trials and results in systemic treatment of HCC.

S. Faivre, M. Reig, L. D. da Fonseca, 2018, Journal of hepatology.

Bcl-2 and CCND1/CDK4 expression levels predict the cellular effects of mTOR inhibitors in human ovarian carcinoma

G. Kroemer, P. Boya, E. Raymond, 2004, Apoptosis.

Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors

E. Raymond, S. Faivre, S. Albert, 2011, Targeted Oncology.

Cetuximab as first-line monotherapy in patients with unresectable squamous cell carcinoma of the skin: Preliminary results of a phase II multicenter study

P. Petrow, S. Faivre, M. Avril, 2008 .

Selective Oral MEK1/2 Inhibitor Pimasertib in Metastatic Melanoma: Antitumor Activity in a Phase I, Dose-Escalation Trial

E. Raymond, J. Schellens, A. Italiano, 2020, Targeted Oncology.

First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant Fibroblast Growth Factor 19 Signaling as a Driver Event in Hepatocellular Carcinoma.

Nicolas Stransky, V. Mazzaferro, J. Llovet, 2019, Cancer discovery.

Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.

J. Pignon, M. Ducreux, T. Greten, 2014, The Lancet. Oncology.

Imaging response in neuroendocrine tumors treated with targeted therapies: the experience of sunitinib

M. Ronot, V. Vilgrain, E. Raymond, 2012, Targeted Oncology.

Effects of adjuvant chemotherapy on the natural history and likelihood of therapeutic efficacy in advanced breast cancer patients: a critical literature review.

S. Faivre, E. Cvitkovic, J. Alexandre, 1998, Cancer treatment reviews.

Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?

E. Raymond, C. Robert, J. Armand, 2005, Annals of internal medicine.

Impact of the COVID-19 Outbreak on the Management of Patients with Cancer

Catherine Thieblemont, E. Raymond, S. Faivre, 2020, Targeted Oncology.

Multimodal strategy for the management of sphenoid osteoradionecrosis: Preliminary results

S. Faivre, P. Herman, J. Guichard, 2020, Laryngoscope investigative otolaryngology.

End points for new agents in induction chemotherapy for locally advanced head and neck cancers.

J. Bourhis, E. Raymond, C. Monnerat, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Preoperative sequential chemotherapy in locally advanced squamous cell carcinoma of the head and neck

E. Raymond, J. Armand, F. Janot, 2005, Head & neck.

Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines

I. Bièche, E. Raymond, S. Faivre, 2008, Cancer Chemotherapy and Pharmacology.

Novel transforming growth factor beta receptor I kinase inhibitor galunisertib (LY2157299) in advanced hepatocellular carcinoma

G. Giannelli, E. Raymond, A. Santoro, 2019, Liver international : official journal of the International Association for the Study of the Liver.

Suppression of Cellular Invasion by Activated G-Protein Subunits Gαo, Gαi1, Gαi2, and Gαi3 and Sequestration of Gβγ

M. Mareel, E. Bruyneel, S. Faivre, 2001 .

Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells

J. Lord, E. Raymond, S. Faivre, 2008, Molecular Cancer Therapeutics.

Biological and Prognostic Relevance of Mitogen-Activated Protein Kinases in Pancreatic Adenocarcinoma

P. Bedossa, A. Sauvanet, S. Faivre, 2012, Pancreas.

Factors P redicting f or E fficacy a nd S afety o f D ocetaxel i n a C ompassionate-Us e C ohort o f 8 25 H eavily P retreated Advanced B reast C ancer P atients

J. Bonneterre, P. Viens, S. Faivre, 2000 .

Phase I and pharmacokinetic study of etaracizumab (Abegrin), a humanized monoclonal antibody against alphavbeta3 integrin receptor, in patients with advanced solid tumors.

E. Raymond, S. Faivre, M. Marty, 2008, Investigational new drugs.

Recent developments of c‐Met as a therapeutic target in hepatocellular carcinoma

E. Raymond, S. Faivre, A. Cheng, 2018, Hepatology.

First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials

V. Gebski, P. Gibbs, F. Lammert, 2017, The Lancet. Oncology.

Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients

R. Kaiser, E. Raymond, F. Goldwasser, 2011, British Journal of Cancer.

A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors

E. Raymond, F. Goldwasser, S. Faivre, 2006, Investigational new drugs.

Spectrum of Cellular Responses to Pyriplatin, a Monofunctional Cationic Antineoplastic Platinum(II) Compound, in Human Cancer Cells

Katherine S. Lovejoy, I. Bièche, E. Raymond, 2011, Molecular Cancer Therapeutics.

Strong antineoplastic effects of metformin in preclinical models of liver carcinogenesis.

V. Paradis, B. V. Van Beers, P. Bedossa, 2016, Clinical science.

O126 EVALUATION OF LY2157299 MONOHYDRATE (LY), A TGF-β RECEPTOR I KINASE INHIBITOR, IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA: PHASE 2 STUDY RESULTS OF SAFETY, EFFICACY AND PK/PD

G. Giannelli, E. Raymond, A. Santoro, 2014 .

Oxaliplatin in colorectal cancer: an overview.

M. Ducreux, E. Raymond, J. Armand, 2000, Seminars in oncology.

Stromal expression of SPARC in pancreatic adenocarcinoma

E. Raymond, S. Faivre, P. Hammel, 2013, Cancer and Metastasis Reviews.

A Phase II Multicentre, Open-Label, Proof-of-Concept Study of Tasquinimod in Hepatocellular, Ovarian, Renal Cell, and Gastric Cancers

H. Mackay, A. Oza, R. Plummer, 2017, Targeted Oncology.

Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study.

Y. Bang, E. Van Cutsem, E. Raymond, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Novel molecular therapies in hepatocellular carcinoma

E. Raymond, S. Faivre, M. Bouattour, 2011, Liver international : official journal of the International Association for the Study of the Liver.

Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression

E. Raymond, A. Fasolo, E. Assenat, 2021, British Journal of Cancer.

Changes in Tumor Density in Patients with Advanced Hepatocellular Carcinoma Treated with Sunitinib

Mohamed Bouattour, Xun Lin, Yoon-Koo Kang, 2011, Clinical Cancer Research.

PD-020Tolerability and activity of second-line tepotinib, a potent and highly selective c-MET inhibitor, in patients with advanced hepatocellular carcinoma previously treated with sorafenib

E. Raymond, A. Fasolo, S. Faivre, 2016 .

E. Raymond, J. Douillard, Jun Suk Kim, 2011, Journal of Translational Medicine.

The role of integrins in colorectal cancer.

E. Raymond, S. Faivre, C. le Tourneau, 2007, Oncology.

Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells.

I. Bièche, E. Raymond, M. Vidaud, 2009, Cancer research.

Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma

M. Ziol, C. Copie-Bergman, S. Imbeaud, 2020, Hepatology.

Methods for Adjusting for Bias Due to Crossover in Oncology Trials

S. Faivre, I. Proskorovsky, K. Ishak, 2014, PharmacoEconomics.

Determination of an optimal response cut-off able to predict progression-free survival in patients with well-differentiated advanced pancreatic neuroendocrine tumours treated with sunitinib: an alternative to the current RECIST-defined response

E. Raymond, H. Lenz, S. Faivre, 2017, British Journal of Cancer.

[Epidermal growth factor inhibitors].

E. Raymond, S. Faivre, C. Delbaldo, 2003, La Revue de medecine interne.

Abstract 3000: Angiogenic recovery under chronic exposure to sunitinib is associated with vasculogenic mimicry in renal cell carcinoma

E. Raymond, S. Faivre, M. Serova, 2014 .

Medical oncologists must get more involved in systemic treatment of hepatocellular carcinoma.

L. Rimassa, S. Faivre, J. Raoul, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Antitumor activity of imatinib in progressive, highly expressing KIT adenoid cystic carcinoma of the salivary glands: A phase II study

F. Bidault, E. Raymond, F. Janot, 2007 .

Abstract B175: TGF-β-RI kinase inhibitors LY2157299 and LY364947 decrease motility and invasion in hepatocarcinoma (HCC) cells developing resistance to VEGFR/PDGFR kinase inhibitors.

I. Bièche, E. Raymond, S. Faivre, 2011 .

217 Specific TGF-beta receptor-I inhibition using LY364947 impairs signaling, motility, and invasion in parental and multikinase inhibitor-resistant hepatocarcinoma cells

I. Bièche, E. Raymond, S. Faivre, 2010 .

[PI3K-AKT-mTOR pathway and cancer].

E. Raymond, S. Faivre, C. Dreyer, 2012, Bulletin du cancer.

Cetuximab as first-line monotherapy in patients with skin unresectable squamous cell carcinoma: Final results of a phase II multicenter study.

P. Petrow, S. Faivre, L. Lacroix, 2010 .

Increased anticancer activity of the thymidylate synthase inhibitor BGC9331 combined with the topoisomerase I inhibitor SN-38 in human colorectal and breast cancer cells: induction of apoptosis and ROCK cleavage through caspase-3-dependent and -independent mechanisms.

C. Tournigand, E. Raymond, S. Faivre, 2005, International journal of oncology.

Phase I study of ixabepilone given every other week in combination with irinotecan in patients with advanced malignancies.

E. Raymond, J. Armand, S. Faivre, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies.

E. Raymond, J. Armand, S. Faivre, 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study

Y. Bang, E. Van Cutsem, E. Raymond, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Surgical Results after Downstaging of Initially Marginal or Non-Resectable Liver Metastases

J. Belghiti, S. Faivre, F. Cauchy, 2012, Digestive Diseases.

BIOSHARE multicenter neoadjuvant phase 2 study: Results of pre-operative sorafenib in patients with resectable hepatocellular carcinoma (HCC)—From GERCOR IRC.

M. Ronot, V. Paradis, E. Raymond, 2016 .

Efficacy and safety of the Met inhibitor tepotinib in patients (pts) with advanced Met+ hepatocellular carcinoma (HCC) previously treated with sorafenib.

A. Fasolo, E. Assenat, S. Faivre, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

In vitro Anti-proliferative Effects of ProLindac™, a Novel Dach-Platinum-Linked Polymer Compound, as a Single Agent and in Combination with Other Anti-cancer Drugs

E. Raymond, S. Faivre, M. Serova, 2009 .

[Prognosis factors of cholangiocarcinoma: contribution of recent molecular biology tools].

V. Paradis, E. Raymond, J. Belghiti, 2009, Bulletin du cancer.

[Zd 1839 "Iressa"].

E. Raymond, J. Armand, C. Monnerat, 2000, Bulletin du cancer.

Neuroendocrine tumors and CUP

A. Carrato, M. Kudo, R. Salazar, 2012 .

mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?

E. Raymond, S. Faivre, M. Serova, 2008, British Journal of Cancer.

Results of a phase I study of DTS-201, a peptidic prodrug of doxorubicin, in patients with solid tumors

J. Robert, S. Faivre, E. Brain, 2007 .

BERIL-1: A phase II, placebo-controlled study of buparlisib (BKM120) plus paclitaxel in patients with platinum-pretreated recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).

Sung-Bae Kim, A. Dechaphunkul, É. Remenár, 2016 .

704 POSTER A phase I dose escalation and pharmacokinetic study of BIBF 1120, a novel tyrosine kinase inhibitor against VEGFR, PDGFR and FGFR, in combination with docetaxel in advanced chemonaive hormone refractory prostate cancer patients (HRPC)

R. Kaiser, E. Raymond, F. Goldwasser, 2007 .

A phase I study of AVE1642, a human monoclonal antibody-blocking insulin-like growth factor-1 receptor (IGF-1R), given as a single agent and in combination with sorafenib as first-line therapy in patients with advanced hepatocellular carcinoma (HCC).

E. Raymond, S. Faivre, C. Dreyer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Benefits from pharmacological and pharmacokinetic properties of sunitinib for clinical development

E. Raymond, S. Faivre, C. Dreyer, 2010, Expert opinion on drug metabolism & toxicology.

Specificities and challenges of imaging response in pancreatic neuroendocrine tumors treated with targeted therapies

S. Faivre, C. Dreyer, M. Bouattour, 2012 .

Abstract A72: A first-in-man Phase I study of the galectin-1 (gal-1) inhibitor OTX008 given subcutaneously as a single agent to patients with advanced solid tumors.

G. Rabinovich, E. Raymond, P. Hérait, 2013 .

[Molecular mechanism in the regulation of apoptosis].

S. Faivre, 1998, Bulletin du Cancer.